Background
Methods
Patients
Test group
Patient | Clinical type | Gene | Type variant | Nucleotide | Protein | Classification |
---|---|---|---|---|---|---|
RP-808 | USH1 |
CDH23
| Intronic | c.6059-9G > A | ----- | Pathogenic. UV4 |
USH1G
| Missense | c.387A > G | p.Lys130Glu | UV1 | ||
USH1G
| Missense | c.423G > A | p.Glu142Lys | UV2 | ||
RP-1145 | USH2 |
USH2A
| Frameshift duplication | c.10272-10274dup | p.Cys3425Phefs*4 | Pathogenic. UV4 |
USH2A
| Nonsense | c.7854G > A | p.Trp2618* | Pathogenic. UV4 | ||
DFNB31
| Isocoding | c.117G > A | p.Val39Val | UV1 | ||
RP-1286§ | USH1 |
PCDH15
| Frameshift insertion | c.1304_1305insC | p.Thr436Tyrfs*12 | Pathogenic. UV4 |
RP-1374 | USH1 |
PCDH15
| Nonsense | c.7C > T | p.Arg3* | Pathogenic. UV4 |
RP-1426 | USH1 |
MYO7A
| Missense | c.6610G > C | p.Ala2204Pro | Pathogenic |
RP-1522 | USH2 |
USH2A
| Frameshift deletion | c.2299delG | p.Glu767Serfs*21 | Pathogenic. UV4 |
CDH23
| Missense | c.1096G > A | p.Ala366Thr | UV2 | ||
RP-1608§ | USH3 |
USH2A
| Missense | c.9799 T > C | p.Cys3267Arg | Pathogenic. UV4 |
RP-1614 | USH1 |
MYO7A
| Frameshift deletion | c.6025delG | p.Ala2009Profs*32 | Pathogenic. UV4 |
RP-1637 | USH2 |
USH2A
| Frameshift duplication | c.5540dupA | p.Asn1848Glufs*20 | Pathogenic. UV4 |
USH2A
| Large deletion | Del IVS4_IVS9 | p.Gly262Valfs*2 | Pathogenic. UV4 | ||
RP-1757§ | Atypical |
MYO7A
| In-frame deletion | c.655_660del | p.Ile219_His220del | Pathogenic. UV4 |
RP-1760 | USH2 |
USH2A
| Missense | c.2296 T > C | p.Cys766Arg | UV3 |
Cohort of USH patients previously unscreened
DNA Samples
Targeted next generation sequencing design
Chr | Gene | RefSec | Coding exons | Size (bp) | Coding Size (bp) | Amino acids | Alternative Ref Sec | Additional exons and the intronic USH2A region included in the study | Size (bp) | Number of exons analyzed |
---|---|---|---|---|---|---|---|---|---|---|
11 |
MYO7A
| NM_000260.3 variant 1 | 48 | 7465 | 6648 | 2215 | 48 | |||
10 |
CDH23
| NM_022124.5 variant 1 | 69 | 11134 | 10065 | 3354 | NM_052836.3 variant 2 | 1 | 150 | 70 |
10 |
PCDH15
| NM_033056.3 variant C | 32 | 7021 | 5868 | 1955 | NM_001142773.1 variant H | 1 | 6 | 38 |
NM_001142769.1 variant I | 2 | 871 | ||||||||
NM_001142771.1 variant K | 2 | 4469 | ||||||||
11 |
USH1C
| NM_153676 variant 3 | 27 | 3246 | 2700 | 899 | NM_005709.3 variant 1 | 1 | 75 | 28 |
17 |
USH1G
| NM_173477.4 variant 1 | 3 | 3565 | 1386 | 461 | 3 | |||
15 |
CIB2
| NM_006383.2 variant 1 | 6 | 1580 | 564 | 187 | 6 | |||
1 |
USH2A
| NM_206933.2 variant 2 | 71 | 18883 | 15609 | 5202 | NC_000001.11 | c.7595-2144A > G | 152 | 71 + 1 intronic sequence |
5 |
GPR98
| NM_032119.3 variant 1 | 90 | 19333 | 18921 | 6307 | 90 | |||
9 |
DFNB31
| NM_015404.3 variant 1 | 12 | 4079 | 2724 | 907 | NM_001083885.2 variant 2 | 1 | 110 | 13 |
3 |
CLRN1
| NM_174878.2 variant 1 | 3 | 2359 | 699 | 232 | NM_052995.2 variant 4 | 1 | 20 | 4 |
10 |
PDZD7
| NM_001195263.1 variant 1 | 17 | 4164 | 3102 | 1033 | NM_024895.4 variant 2 | 1 | 285 | 18 |
5 |
HARS
| NM_002109.5 variant1 | 13 | 2322 | 1530 | 509 | 13 | |||
17 |
MYO15A
| NM_016239.3 | 65 | 11876 | 10593 | 3530 | 65 | |||
12 |
VEZT
| NM_017599 variant 1 | 12 | 4580 | 2340 | 779 | NR_038242.1 variant 2 | 1 | 74 | 13 |
Total targets | 481 |
Sequence capture and next generation sequencing
Variant analysis
Copy number variation analysis and validation
Results
Next generation sequencing results of the USH panel
Test group: validation of the diagnostic strategy
Patient | Clinical type | Gene | Exon | Nucleotide variant | Protein variant | Reference | Segregation analysis |
---|---|---|---|---|---|---|---|
Patients with two pathogenic mutations in the same gene
| |||||||
RP-807 | USH2 |
MYO7A
| 40 |
c.5516 T > C
|
p.Leu1839Pro
| Novel. UV3 | Yes |
MYO7A
| 27 |
c.3503G > A
|
p.Arg1168Gln
| Novel. UV3 | |||
RP-808¶ | USH1 |
CDH23
| 47 | c.6059-9G > A | --- | von Brederlow et al., (2002) [40] | No |
CDH23
| 10 |
c.871G > A
|
p.Gly291Arg
| Novel. UV3 | |||
RP-890 | USH3 |
USH2A
| 26 | c.5278delG | p.Asp1760Metfs*10 | Garcia-Garcia et al., (2011) [41] | No |
USH2A
| 26 | c.5278delG | p.Asp1760Metfs*10 | Garcia-Garcia et al., (2011) [41] | |||
RP-1182 | USH1 |
PCDH15
| 22_23 |
Duplication exons 22_23
| --- | Novel. UV4 | No |
PCDH15
| 22_23 |
Duplication exons 22_23
| --- | Novel. UV4 | |||
RP-1183 | USH1 |
CDH23
| 26 | c.3016G > A | p.Glu1006Lys | Schultz et al., (2011) [42] | No |
CDH23
| 26 | c.3016G > A | p.Glu1006Lys | Schultz et al., (2011) [42] | |||
RP-1234 | USH1 |
MYO7A
| 43 |
c.5884delTTCT
|
p.Phe1962Leufs*7
| Novel. UV4 | Yes |
MYO7A
| 43 |
c.5884delTTCT
|
p.Phe1962Leufs*7
| Novel. UV4 | |||
RP-1237 | USH1 |
CDH23
| 46 | c.6049G > A | p.Gly2017Ser | Roux et al., (2006) [43] | No |
CDH23
| 46 | c.6049G > A | p.Gly2017Ser | Roux et al., (2006) [43] | |||
RP-1374¶ | USH1 |
PCDH15
| 2 | c.7C > T | p.Arg3* | Ahmed et al., (2001) [44] | Yes |
PCDH15
| 27 | c.3717 + 2dupT | --- | Jaijo et al., (2012) [45] | |||
RP-1422 | USH1 |
MYO7A
| 43 | c.5944G > A | p.Gly1982Arg | Riazuddin et al., (2008) [46] | Yes |
MYO7A
| 43 | c.5944G > A | p.Gly1982Arg | Riazuddin et al., (2008) [46] | |||
RP-1522¶ | USH2 |
USH2A
| 13 | c.2299delG | p.Glu767Serfs*21 | Liu et al., (1999) [47] | No |
USH2A
| 20 |
Deletion exon 20
|
---
| Novel. UV4 | |||
RP-1551 | USH1 |
PCDH15
| 27 |
c.3511delA
|
p.Asp1172Ilefs*13
| Novel. UV4 | Yes |
PCDH15
| 27 |
c.3511delA
|
p.Asp1172Ilefs*13
| Novel. UV4 | |||
RP-1614¶ | USH1 |
MYO7A
| 44 | c.6025delG | p.Ala2009Profs*32 | Bharadwaj et al., (2000) [48] | No |
MYO7A
| 40 |
c.5537C > A
|
p.Pro1846His
| Novel. UV3 | |||
RP-1760¶ | USH2 |
USH2A
| 55 |
c.10888delA
|
p.Gly3631Valfs*43
| Novel. UV4 | No |
USH2A
| 13 | c.2296 T > C | p.Cys766Arg | Glöcke et al., (2013) [35] | |||
RP-1781 | USH2 |
CDH23
| 29 |
Duplication exon 29
| --- | Novel. UV4 | No |
CDH23
| 68 |
c.9569C > T
|
p.Ala3190Val
| Novel. UV3 | |||
RP-1791 | USH1 |
MYO7A
| 20 | c.2283-1G > T | --- | Roux et al., (2006) [43] | Yes |
MYO7A
| 28 | c.3594C > A | p.Cys1198* | Roux et al., (2011) [43] | |||
RP-1802 | USH2 |
USH2A
| 63 | c.13811 + 2 T > G | --- | Besnard et al., (2014) [37] | No |
USH2A
| 50 | c.9799 T > C | p.Cys3267Arg | Aller et al., (2006) [49] | |||
RP-1835 | USH2 |
USH2A
| 57 | c.11065C > T | p.Arg3689* | Le Quesne Stabej et al., 2012 [50] | Yes |
USH2A
| 22 |
c.4758 + 3A > G
|
---
| Novel. UV3 | |||
RP-1864 | USH2 |
MYO7A
| 6 | c.494C > T | p.Thr165Met | Ouyang et al., (2005) [51] | No |
MYO7A
| 6 | c.494C > T | p.Thr165Met | Ouyang et al., (2005) [51] | |||
RP-1895 | USH2 |
GPR98
| 79_83 | Duplication exons 79_83 | --- | Besnard et al., (2012) [52] | No |
GPR98
| 79_83 | Duplication exons 79_83 | --- | Besnard et al., (2012) [52] | |||
RP-1904 | USH2 |
GPR98
| 11 |
c.2145_2149delGTTTT
|
p.Leu715Phefs*6
| Novel. UV4 | Yes |
GPR98
| 14 |
c.2612delG
|
p.Gly871Glufs*8
| Novel. UV4 | |||
RP-1910 | USH1 |
CDH23
| 60 | c.8722 + 1delG | --- | Oshima et al., (2008) [53] | Yes |
CDH23
| 60 | c.8722 + 1delG | --- | Oshima et al., (2008) [53] | |||
RP-1924 | USH1 |
MYO7A
| 39 | c.5392C > T | p.Gln1798* | Janecke et al., (1999) [54] | Yes |
MYO7A
| 27 |
c.3503G > A
|
p.Arg1168Gln
| Novel. UV3 | |||
RP-1927 | USH2 |
USH2A
| 21 | c.4474G > T | p.Glu1492* | Bernal et al., (2005) [55] | Yes |
USH2A
| 2 |
c.269A > G
|
p.Tyr90Cys
| Novel. UV3 | |||
RP-1948 | USH1 |
MYO7A
| 7 |
C.707 T > A
|
p.Leu236Gln
| Novel. UV3 | No |
MYO7A
| 42 | c.5749G > T | p.Glu1917* | Jacobson et al., (2009) [56] | |||
RP-1960 | USH2 |
USH2A
| 25 |
c.5167G > C
|
p.Gly1723Arg
| Novel. UV3 | No |
USH2A
| 7 | c.1214delA | p.Asn405Ilefs*3 | Bernal et al., (2005) [55] | |||
Patients with three pathogenic mutations in two different genes
| |||||||
RP-1847 | USH2 |
USH2A
| 62 | c.12067-2A > C | --- | Kaiserman et al., (2007) [57] | Yes |
USH2A
| 14 | Deletion exon 14 | --- | Glöckle et al., (2013) [35] | |||
USH1G
| 2 |
c.805C > T
|
p.Arg269*
| Novel. UV4 | |||
RP-1923 | USH2 |
USH2A
| 62 | c.12093delC | p.Tyr4031* | Garcia-Garcia et al., (2011) [41] | No |
USH2A
| 44 | Deletion exon 44 | --- | Glöckle et al., (2013) [35] | |||
DFNB31
| 9 |
c.2234G > A
|
p.Arg745His
| Novel. UV3 | |||
Patients with only one pathogenic mutation
| |||||||
RP-1455 | USH1 |
USH2A
| 28 |
c.5666A > G
|
p.Asp1889Gly
| Novel. UV3 | No |
RP-1496 | USH3 |
GPR98
| 19 |
c.3443G > A
|
p.Gly1148Asp
| Novel. UV3 | No |
RP-1741 | USH2 |
USH2A
| PE40 | c.7592-2144A > G | --- | Vaché et al., (2012) [58] | No |
RP-1929 | USH2 |
GPR98
| 58 |
c.11974G > A
|
p.Asp3992Asn
| Novel. UV3 | No |
RP-1953 | USH2 |
USH1C
| 18 | c.1859G > T | p.Arg620Leu | Ouyang et al., (2002) [59] | No |
Patients with pathologic mutations in different genes
| |||||||
RP-1426¶ | USH1 |
MYO7A
| 49 | c.6610G > C | p.Ala2204Pro | Jaijo et al., (2007) [60] | Yes |
CDH23
| 39 |
c.5068-2A > T
|
---
| Novel. UV4 | |||
RP-1950 | USH2 |
USH2A
| 70 | c.2299delG | p.Glu767Serfs*21 | Liu et al., (1999) [47] | No |
GPR98
| 70 |
c.14278C > T
|
p.Pro4760Ser
| Novel. UV3 |
Cohort of USH patients previously unscreened
Patient | Gene | Exon | Nucleotide Change | Amino Acid Change | Classification | SIFT (score) | PolyPhen-2 (score) | NetGene2 | Human Splicing Finder | NNSPLICE | RESCUE-ESE |
---|---|---|---|---|---|---|---|---|---|---|---|
RP-1948 |
MYO7A
| 7 | c.707T>A | p.Leu236Gln | UV3 | deleterious (0) | probably_damaging (1) | Neutral | Neutral | Neutral | A new ESE site is created |
RP-807 RP-1924 |
MYO7A
| 27 | c.3503G>A | p.Arg1168Gln | UV3 | deleterious (0) | probably_damaging (1) | Score for the main donor site decreases from 95 to 75 | Score for the main donor site decreases from 90 to 80 | The main donor site is not recognized | Neutral |
RP-807 |
MYO7A
| 40 | c.5516T>C | p.Leu1839Pro | UV3 | deleterious (0) | probably_damaging (1) | Score for the main acceptor site decreases from 80 to 77 | Neutral | Neutral | Neutral |
RP-1614 |
MYO7A
| 40 | c.5537C>A | p.Prp1846His | UV3 | deleterious (0.01) | possibly_damaging (0.85) | Score for the main acceptor site decreases from 80 to 77 and one acceptor site is not recognized | Neutral | Neutral | Neutral |
RP-808 |
CDH23
| 10 | c.871G>A | p.Gly291Arg | UV3 | deleterious (0) | probably_damaging (1) | Neutral | Neutral | Neutral | A new ESE site is created |
RP-1426 |
CDH23
| 39 | c.5068-2A>T | c.5068-2A>T | UV4 | --- | --- | The main acceptor site is not recognized | Score for the main acceptor site decreases from 95 to 66 | The main acceptor site is not recognized | --- |
RP-1781 |
CDH23
| 68 | c.9569C>T | p.Ala3190Val | UV3 | deleterious (0) | probably_damaging (1) | Neutral | Neutral | Neutral | Neutral |
RP-1927 |
USH2A
| 2 | c.269A>G | p.Tyr90Cys | UV3 | tolerated (0.17) | possibly_damaging (0.796) | Score for acceptor site decreases from 82 to 80 | Neutral | Score for acceptor site decreases from 75 to 69 | A ESE site is not recognized |
RP-1835 |
USH2A
| 22 | c.4758+3A>G | c.4758+3A>G | UV3 | --- | --- | The main donor site is not recognized | Neutral | The main donor site decreases from 98 to 73 | --- |
RP-1960 |
USH2A
| 25 | c.5167G>C | p.Gly1723Arg | UV3 | deleterious (0) | probably_damaging (0.994) | The main donor site is not recognized | Score for the main donor site decreases from 86 to 75 | The main donor site is not recognized | Neutral |
RP-1455 |
USH2A
| 28 | c.5666A>G | p.Asp1889Gly | UV3 | deleterious (0) | probably_damaging (0.982) | The main donor and acceptor sites decrease from 82 to 80 and from 53 to 48 respectively and a new acceptor site is created | Neutral | Neutral | Two ESEs are not recognized |
RP-1496 |
GPR98
| 19 | c.3443G>A | p.Gly1148Asp | UV3 | deleterious (0) | probably_damaging (0.999) | Neutral | Neutral | Neutral | Neutral |
RP-1929 |
GPR98
| 58 | c.11974G>A | p.Asp3992Asn | UV3 | deleterious (0.01) | probably_damaging (0.999) | Neutral | Neutral | Neutral | A ESE is not recognized |
RP-1950 |
GPR98
| 70 | c.14278C>T | p.Pro4760Ser | UV3 | deleterious (0) | probably_damaging (0.998) | Neutral | Neutral | Neutral | Neutral |
RP-1923 |
DFNB31
| 9 | c.2234G>A | p.Arg745His | UV3 | deleterious(0.01) | probably_damaging (0.984) | Neutral | Neutral | The main donor site increases from 66 to 86 | Neutral |